Table 1.

Inclusion and Exclusion Criteria.

Inclusion Criteria	Exclusion Criteria
Patients of both sex aged ≥18 years	Age less than 18 years
Histological confirmation of rectal adenocarcinoma	Patients with neoplasia more than 12 cm from the anal margin
Patients undergoing neoadjuvant treatment for locally advanced tumor of the rectum with confirmed major clinical response after neoadjuvant treatment	Patients with stable disease or disease progression after neoadjuvant treatment
Rectal tumor up to 12 cm from the external anal margin	Patients who, for medical reasons, cannot be given bleomycin
Patients must be willing to comply with the study protocol and give their informed written consent	Lesions unsuitable for Electrochemotherapy (ECT) (bony invasion, large vessels infiltration, etc.)
Patients with an Eastern Cooperative Oncology Group (ECOG) status performance <3	Acute lung infection
	Poor lung function symptoms
	Severe coagulation disorders
	Previous allergic reactions to bleomycin
	Previous cumulative bleomycin dose over than 250 mg/m2
	Chronic renal dysfunction (creatinine> 150 µmol/L)
	Pregnancy or lactation